Pakistan Drug Regulator Hits Back At Drug Makers Over Suits
This article was originally published in PharmAsia News
Pakistan's drug regulatory agency has struck back at drug makers and importers by blaming them for causing the problems in their complaints by constantly dragging it into court over drug pricing issues.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.